Abstract
The prostacyclin receptor (IP - International Union of Pharmacology nomenclature) is a member of the seven transmembrane G-protein coupled receptor (GPCR) superfamily. Recent concerns with selective and non-selective COX-1/COX-2 inhibition have exposed an important cardioprotective role for IP in preventing atherothrombosis. Receptor dysfunction (genetic variants) or reduced signaling (COX-2 inhibition) in high cardiovascular risk patients leads to increased cardiovascular events. These clinical observations have also been confirmed genetically by mouse knockout studies. Thus, receptor regulation is paramount in ensuring correct function in the prevention of atherothrombosis. This review summarizes recent literature on how this important receptor is regulated, from transcription to transport (to and from the membrane surface). These regulatory processes are critical in ensuring that IP receptors are adequately expressed and functional on the cell surface.
Keywords: Prostacyclin receptor, activation, desensitization, dimerization, internalization, transcriptional regulation, homeostasis, hemostasis, atherothrombosis, atherosclerosis, inflammatory disease, coronary syndrome, stroke, platelets, restenotic lesions
Current Molecular Medicine
Title: Prostacyclin Receptor Regulation --- from Transcription to Trafficking
Volume: 11 Issue: 7
Author(s): C. Midgett, J. Stitham, K.A. Martin and J. Hwa
Affiliation:
Keywords: Prostacyclin receptor, activation, desensitization, dimerization, internalization, transcriptional regulation, homeostasis, hemostasis, atherothrombosis, atherosclerosis, inflammatory disease, coronary syndrome, stroke, platelets, restenotic lesions
Abstract: The prostacyclin receptor (IP - International Union of Pharmacology nomenclature) is a member of the seven transmembrane G-protein coupled receptor (GPCR) superfamily. Recent concerns with selective and non-selective COX-1/COX-2 inhibition have exposed an important cardioprotective role for IP in preventing atherothrombosis. Receptor dysfunction (genetic variants) or reduced signaling (COX-2 inhibition) in high cardiovascular risk patients leads to increased cardiovascular events. These clinical observations have also been confirmed genetically by mouse knockout studies. Thus, receptor regulation is paramount in ensuring correct function in the prevention of atherothrombosis. This review summarizes recent literature on how this important receptor is regulated, from transcription to transport (to and from the membrane surface). These regulatory processes are critical in ensuring that IP receptors are adequately expressed and functional on the cell surface.
Export Options
About this article
Cite this article as:
Midgett C., Stitham J., Martin K.A. and Hwa J., Prostacyclin Receptor Regulation --- from Transcription to Trafficking, Current Molecular Medicine 2011; 11 (7) . https://dx.doi.org/10.2174/156652411800615144
DOI https://dx.doi.org/10.2174/156652411800615144 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Glycemic Threshold of 90 mg/dl Promotes Early Signs of Atherosclerosis in Apparetly Healthy Overweight/Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Targeting Apoptotic Pathways in Myocardial Infarction: Attenuated by Phytochemicals
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Angiogenesis in the Development of Cardiovascular Diseases)
Current Angiogenesis (Discontinued) The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Current Pharmaceutical Biotechnology Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design NADPH Oxidases in the Heart
Current Cardiology Reviews Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Benefits of Resistance Training in Older Adults
Current Aging Science Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation, Atrial Fibrillation and Cardiac Surgery: Current Medical and Invasive Approaches for the Treatment of Atrial Fibrillation
Current Pharmaceutical Design Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin
Current Pharmaceutical Design Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design